Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

A different path to specificity for Ras inhibitors

May 3, 2021

Phase IIb/III study of masitinib in metastatic CRPC meets primary endpoint

April 30, 2021

PRT-1419 shows potent antitumor activity in preclinical models

April 30, 2021

First-in-class KAT6A/KAT6B inhibitor PF-9363 shows antitumor activity against ER+ breast cancer

April 30, 2021

Goldfinch Biopharma discovers CDK5 inhibitors

April 30, 2021

Recurium IP Holdings patents ERK-1 and/or ERK-2 inhibitors

April 30, 2021

Enrollment opens in first-in-human study of OMO-103 in solid tumors

April 30, 2021

Boehringer Ingelheim initiates phase I study of BI-1701963 alone or in combination with BI-3011441

April 30, 2021

New phase II study in China evaluates HMPL-689 in follicular lymphoma and marginal zone lymphoma

April 29, 2021

Nanexa initiates phase I study of long-acting azacitidine NEX-18

April 29, 2021

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...